Deep Brain Stimulation Market

Global Deep Brain Stimulation Market Size (2023 to 2028)

The global deep brain stimulation market is estimated to grow at a CAGR of 10.5% between 2023 and 2028.

The human brain functions via thousands of brain cells called neurons. The neurons work and communicate and perform functions by releasing small electrical charges between them. When these electric charges are not adequately released or communicated, we suffer from various diseases and mental conditions. The deep brain stimulator (DBS) is a treatment procedure through which the electrical impulses in the brain are externally stimulated by connecting devices that deliver direct electrical current to the parts of your brain where it is required. 

One or more wires are attached to a small device which is then attached to the patient near the collarbone area and delivers mild electric currents to the regions of the brain which require it. DBS can treat several conditions of the brain like epilepsy, dystonia, Parkinson's disease, essential tremors, obsessive-compulsive disorder (OCD), etc. the procedure can also help in various conditions like Alzheimer's, anxiety, headaches, schizophrenia, etc. 

Impact of COVID-19 on the global deep brain stimulation market:

The pandemic affected various business sectors, and it especially significantly impacted the healthcare sector. The pandemic had a negative impact on the deep brain stimulation market due to the disruption of the supply chain and stringent government lockdowns. Many companies and firms faced a financial downside and thus faced losses. In addition, the pandemic made it necessary to prioritize the COVID-19 patients over all other medical conditions, including mental conditions, so the brain surgeries, diagnoses, and treatments were delayed pushing the market further back. 

However, the pandemic increased the acceptability of tele-consultancy to perform routine check-ups in patients with Parkinson's disease during the pandemic, which is expected to lead the market towards development in the coming years. additionally, it eased restrictions and lockdowns, and the resuming of surgical procedures will ensure the market come back.

MARKET DRIVERS:

The increasing need for minimally invasive techniques in treating mental disorders, along with elevated patient outcomes, are driving the deep brain stimulation market growth.

The deep brain stimulation market is expected to progress due to the rising technological advancements, research, and developments worldwide. For instance, improved microelectrode designs, rechargeable implantable pulse generators, personalized directed programming, robot-assisted implantation, and others make the DBS treatment system preferable over other drug treatments. On the other hand, the side effects of drug treatments can leave a lasting impact on the patients. For instance, the continuous dosage of a drug called levodopa may result in dyskinesia and hallucinations. Additionally, a rise in awareness about the DBS treatment, a targeted system with a lower risk of side effects and is a long-term solution to brain disorders on the market, is expected to witness market development. 

The growing number of FDA approvals, Y-O-Y rise in the geriatric population worldwide, and increased rate of mental disorders and conditions fuel deep brain stimulation market growth.

The increased cases of mental conditions and patients suffering from Parkinson's disease, dystonia, multiple sclerosis, and many other involuntary movements are leading the market towards progress. Neurological disorders contribute around 6.3% to the global disease burden, and it has become one of the significant causes of mortality around the world, accounting for about 13.2% of deaths in developed countries and 16.8% in middle and low-income countries, according to WHO statistics. 

MARKET RESTRAINTS:

The high costs of treatment in deep brain stimulation and the stringent guidelines during approval by the FDA, various difficulties faced during the clinical trials, manufacturing, and production due to limited expertise in the field and a lack of skilled professionals, and unfavorable reimbursement policies are expected to hinder the growth of the deep brain stimulation market. 

REPORT COVERAGE:

This market research report on the global deep brain stimulation market has been segmented and sub-segmented based on type, application, end-use, and region.

Global Deep Brain Stimulation Market - By Product:

• Single Channel
• Dual-Channel

Based on the product, the dual-channel dominated the deep brain stimulation market in 2022 with a share of 54.22% due to the high usage of the segment in surgeries and requirements for PD surgical procedures. In addition, the technological advancements in the segment enabled it to be used by multiple hospitals, thus its dominance. 

However, the single-channel segment is expected to grow at a healthy CAGR during the forecast period because healthcare professionals believe it provides more programming options. Thus, the preference for the single-channel has propelled and is estimated to grow during the forecast period. 

Global Deep Brain Stimulation Market - By Type:

• Subthalamic DBS
• Globus Pallidus DBS
• Thalamic DBS
• Pedunculopontine Nucleus DBS

By type, the subthalamic DBS segment is predicted to lead the global deep brain stimulation market during the forecast period. Growing government support and raising awareness over the availability of different techniques in healthcare are leveling up the market's growth.

The globus pallidus DBS segment is growing at a higher rate in the coming years.

Global Deep Brain Stimulation Market - By Application:

• Pain Management
• Epilepsy
• Essential Tremor
• Obsessive-Compulsive Disorder (OCD)
• Depression
• Dystonia
• Parkinson’s Disease
• Others

Based on the application, the Parkinson’s disease segment accounted for a 61.8% share in the global deep brain stimulation market in 2022, owing to the increased FDA approvals of the DBS therapies for PD in the U.S and the increased cases of PD worldwide. In addition, there is growing awareness about the advanced treatment of epilepsy and development in the healthcare and infrastructure, consequently leading to the segment's growth during the forecast period. 

Global Deep Brain Stimulation Market - By End-Use:

• Hospitals
• Neurology Clinics
• Ambulatory Surgical Centres
• Research Centres

Based on the end-user, the hospital segment registered a share of 53.3% in the global deep brain stimulation market in 2022, and the dominance of this segment is anticipated to continue throughout the forecast period due to the technological advancement and increased number of surgeries performed in hospitals, along with rising cases of PD and favorable reimbursement.

However, the ambulatory surgical centers segment is expected to develop at a significant CAGR during the forecast period due to lower costs than hospitals, better patient care, and lower risk of infections. 

Global Deep Brain Stimulation Market – By Region:

• North America
  • The U.S.
  • Canada
  • Rest of North America
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of EU
• Asia-Pacific
  • India
  • China
  • Japan
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Rest of Latin America
• Middle East
• Africa

Geographically, the North American region led the deep brain stimulation market worldwide in 2022 and is expected to continue to be dominating during the forecast period due to the presence of key market players in the region along with increased government initiatives and support and increased FDA approvals in countries like the U.S. and Canada. For example, the MRI labeling RNS system of the NeuroPace was approved by the U.S FDA in March 2020. moreover, increased cases of psychiatric disorders in the U.S and Canada will lead the market to grow in the region. 

Asia-Pacific is also expected to contribute significantly to the global deep brain stimulation market during the forecast period due to the increased awareness about neurological disease treatment options, rising cases of neurodegenerative disorders, and a need for long-term solutions that will lead the market to grow. Furthermore, with the establishment of organizations in countries like India, China, Japan, South Korea, and others, the market is predicted to prosper in this region. For instance, the past three years have seen significant growth in the number of DBS centers in China, with more than 200 DBS leads being implanted yearly. 

TOP COMPANIES IN THIS MARKET:

Some of the prominent players operating in the deep brain stimulation market and profiled in this report are Neuropace, Synapse Biomedical Inc., MicroTransponder Inc., Aleva Neurotherapeutics SA, NeuroSigma, Medtronic, Boston Scientific Corporation, Cyberonics Inc., Nervo Corp., Cyberonics Inc., Zynex Medical, Functional Neuromodulation Ltd., Abbott and Reshape Lifesciences Inc.

RECENT MARKET DEVELOPMENTS:

• In 2019, Teijin Limited (Teijin) and NeuroSigma agreed to collaborate. (From Japan) Teijin Pharma, Teijin's healthcare business's core division, has been granted exclusive rights to market NeuroSigma's Monarch eTNS product in Japan and the company's TNS patent rights for the non-invasive treatment of ADHD.
• In 2018, Abbott and the National Institutes of Health (NIH) signed a deal. (United States). According to the agreement, Abbott will donate neuromodulation instruments, such as lateral DBS, SCS, and DRG treatment, to the NIH for research into their applications in chronic pain and progressive movement disorders.
• In 2017, Medtronic and Mercy (US) partnered to form a virtual data sharing and testing network to help collect science data for medical device innovation and patient access.